WASHINGTON, June 25 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.
The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller study which, while positive, were not robust enough to convince the committee that they could be reproduced.
13:23 Alabama Inmate Whose Execution Had Been Delayed Seven Times Has Been Put to Death24
09:05 Alabama executes Tommy Arthur, who escaped 7 prior execution dates20
09:05 Tommy Arthur, Inmate Who Escaped Death 7 Times, Is Executed17
22:41 The Latest: Supreme Court issues temporary stay on execution17